Image: AI-generated editorial illustration
Paris-based Orakl Oncology said it raised an oversubscribed $34 million Series A on November 12, with the round co-led by Norrsken VC and Singular. The startup said the new capital will help expand its platform, O-Predict, which combines patient-derived tumor models and artificial intelligence to predict how cancer drugs will perform before clinical trials.
What did Orakl Oncology announce on November 12?
Orakl Oncology said it raised an oversubscribed $34 million Series A to expand its cancer drug-response prediction platform. The Paris-based company said the financing brought its total funding to $50 million, following earlier rounds of €3 million in 2023 and €11 million in 2024.
The company, which was spun out of Gustave Roussy in 2023, uses patient-derived tumor models and artificial intelligence to predict how cancer drugs will perform. Orakl markets the prediction technology as O-Predict, with SCOPE v2 as the AI model behind the offering.
Who backed the round?
The Series A was co-led by Swedish investor Norrsken VC and French venture firm Singular. Reported new investors included InfraVia, Serena, Bpifrance’s Patient Autonome Fund, teampact.ventures and Plug and Play, while existing investors Verve Ventures, Speedinvest and HCVC also participated.
Norrsken VC said the round reflected a problem in oncology development, noting that around 95% of oncology drugs entering clinical development fail to reach approval and that around 75% of candidates fail in Phase II. InfraVia described Orakl as a TechBio company using artificial intelligence and real patient biology to predict how cancer drugs will perform in clinical trials.
InfraVia also said the round included angel investors Thomas Wolf, Stan Polu, Jacques Boitreaud and Mostafa El Sayed. It added that Orakl brought in advisor Philip Tagari, insitro's chief scientific officer and a former Amgen executive, who spent 24 years at Amgen, led more than 600 discovery scientists globally and helped bring Lumakras and Imdelltra to patients.
What does Orakl say it will do with the money?
Orakl said the financing will support expansion of its platform for cancer-drug-response prediction. A separate Brief report said the company plans to expand its hospital network, make predictions across more than 10 drug programs and discover and validate therapeutic co-targets.
The company also said it plans to increase experimental data generation fivefold, expand into lung and gastric cancers, and establish teams in the U.S. and U.K. InfraVia attributed to CEO Fanny Jaulin that the funding will expand Orakl's capabilities across more cancer types and pharmaceutical programs.
The financing follows July agreements giving Orakl exclusive rights to evaluate four Sanofi oncology assets.
What do the company’s results and next steps look like?
Orakl's April SCOPE preprint said the model was developed using 54 treatment lines from 52 patients and a biobank of 81 organoid lines. Researchers evaluated SCOPE predictions against 32 treatment arms from 23 published colorectal and pancreatic cancer trials and correctly identified the better-performing treatment in seven of eight comparisons.
European Biotechnology said the reported 90% accuracy was mainly based on retrospective validation against published trial outcomes, with conventional chemotherapy making up 88% of treatment arms. Brief reported that in an April 2026 preprint, external validation showed R² of 0.85 for median progression-free survival and 0.71 for objective response rate.
Brief also reported that Orakl's technology is not intended to recommend individual patient care and is not yet ready for clinical use, attributing that statement to Pagès. The same report said Orakl signed five hospital partnerships in 2026, grew to more than 40 employees and had about 30% of staff holding doctoral degrees.
HIT Consultant said Orakl is converting initial engagements into multi-year collaborations and is negotiating contracts with more than 15 additional cancer centers across Europe, North America and Asia. It also reported that notable angel investors included Thomas Wolf, Stan Polu, Jacques Boitreaud and Mostafa El Sayed.
Brief said Orakl's O-Target product focuses on discovering therapeutic targets. The company said it intends to use the new funding to deepen its data generation and broaden its reach across additional cancers and drug programs as it moves beyond its current hospital network.
Sources
- Orakl raises $34M to scale AI platform predicting cancer drug responseseuropean-biotechnology.com· European Biotechnology Magazine
- Orakl Oncology Raises $34M to Scale Virtual Cancer Patient Cohortshitconsultant.net· HIT Consultant
- Orakl Oncology Raises $34M to Expand AI-Powered Cancer Drug Predictionbrief.news· Brief
- Why we've invested in Oraklnorrsken.vc· Norrsken VC
- InfraVia Growth invests in Orakl Oncology to make cancer drug response predictable before clinical trialsinfraviacapital.com· InfraVia Capital Partners



